Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

New breakthrough drugs and research could help to end major global epidemics such as malaria and HIV. But U.S. funding cuts ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...